Updating the MASH pharmacotherapy landscape: a network meta-analysis incorporating SGLT2 inhibitors and emerging combination therapies - Takeaways - MDSpire

Updating the MASH pharmacotherapy landscape: a network meta-analysis incorporating SGLT2 inhibitors and emerging combination therapies

  • By

  • Mengshi Tang

  • Yingxu Ma

  • Yating Wang

  • June 4, 2026

  • 0 min

Share

  • 1

    The study systematically ranked the efficacy and tolerability of pharmacological agents for metabolic dysfunction-associated steatohepatitis (MASH).

  • 2

    FGF21 analogs and SGLT2 inhibitors showed the highest efficacy for fibrosis improvement in the network meta-analysis.

  • 3

    GLP-1/GIP dual agonists and FGF21 analogs demonstrated the highest efficacy for MASH resolution, with SGLT2 inhibitors also providing significant benefits.

  • 4

    SGLT2 inhibitors occupied the 'Optimal Zone' for balancing fibrosis efficacy and tolerability, though this is based on limited histological data.

  • 5

    Further adequately powered Phase 3 trials are warranted to confirm the histological benefits of SGLT2 inhibitors in MASH treatment.

Original Source(s)

Updating the MASH pharmacotherapy landscape: a network meta-analysis incorporating SGLT2 inhibitors and emerging combination therapies

  • by Mengshi Tang, Yingxu Ma, Yating Wang

  • June 4, 2026

Related Content

Proteins at the intersection of circadian rhythms and metabolic dysfunction-associated steatotic liver disease: an 18-protein panel as a novel predictive biomarker set

Single-cell CyTOF analysis uncovers changes in B, T, and macrophage populations in aging mouse liver

Targeting macrophages in liver fibrosis